Back to Search
Start Over
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.
- Source :
- Expert Review of Pharmacoeconomics & Outcomes Research; Oct2019, Vol. 19 Issue 5, p537-549, 13p
- Publication Year :
- 2019
-
Abstract
- Introduction: Early biological treatment of rheumatoid arthritis (RA) may reverse the autoimmune response in some patients resulting in favorable long-term outcomes. Although the cost-effectiveness of this strategy has been questioned, biosimilar entries warrant the revision of clinical and pharmaco-economic evidence. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) published up to 24 May 2018 in Pubmed, EMBASE and Cochrane CENTRAL, comparing infliximab with non-biological therapy in patients with RA naïve to methotrexate. We performed meta-analyses for efficacy outcomes at month 6 and years 1 and 2. Six RCTs were identified, involving 1832 patients. At month 6 ACR70 response and remission, and at year 1 ACR20/ACR70 responses and remission were improved significantly with first-line infliximab versus control. The differences were not significant at year 2. We reviewed cost-utility studies, up to 31 October 2018 in PubMed, Cochrane CENTRAL and the CRD HTA databases. Four studies indicated that first-line use of originator infliximab calculated at 2005–2008 prices was not cost-effective. Expert opinion: We demonstrated the efficacy benefits of first-line infliximab therapy up to 1 year in methotrexate-naïve RA. We highlighted the need for standardized reporting of outcomes and conducting cost-effectiveness analyses of first-line biosimilar therapy in RA. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14737167
- Volume :
- 19
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publication Type :
- Academic Journal
- Accession number :
- 138399832
- Full Text :
- https://doi.org/10.1080/14737167.2019.1647104